Middle East & Africa Antibody Drug Conjugates Market Size and Forecast (2021 - 2031)
The Antibody Drug Conjugates (ADC) market in the Middle East and Africa is projected to grow significantly, reaching approximately US$ 314.4 million by 2031, up from US$ 70.4 million in 2023, reflecting a compound annual growth rate (CAGR) of 20.6% from 2023 to 2031.
Executive Summary and Market Analysis
The ADC market in the Middle East and Africa is divided into key regions including the UAE, South Africa, Saudi Arabia, and the broader Middle East & Africa. Factors such as government initiatives aimed at enhancing pharmaceutical development and the increasing incidence of cancer are driving market growth in this region. The rise in cancer cases, particularly among aging populations, is a primary driver for the ADC market. Technological advancements in ADCs and ongoing research efforts are improving treatment efficacy, making these therapies increasingly appealing for cancer treatment. Additionally, strategic partnerships and collaborations among biopharmaceutical companies are crucial for accelerating ADC development. Increased healthcare investments and the establishment of local biopharmaceutical infrastructures, especially in countries like Saudi Arabia, further contribute to market expansion.
Strategic Insights
Market Segmentation Analysis
The expansion into new therapeutic indications presents significant opportunities within the ADC market. ADCs are designed to deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues, making them highly versatile. This versatility allows for the exploration of ADC applications beyond their initial focus on hematological malignancies and certain solid tumors. Many cancers currently lack effective treatment options, and the introduction of ADCs targeting new biomarkers can offer innovative therapies for these challenging conditions. For example, ADCs are being researched for treating breast, lung, and bladder cancers, where traditional therapies may fall short. Collaborations between pharmaceutical companies and research institutions are fostering innovation in ADC development, focusing on identifying novel targets and optimizing linker technologies to enhance efficacy and safety. A notable example is the study published in July 2025 in the Journal of the Egyptian National Cancer Institute, which explored Patritumab Deruxtecan, a HER3-directed ADC, for EGFR-mutant non-small cell lung cancer (NSCLC) after resistance to EGFR-TKIs, indicating a shift in ADC applications.
By addressing unmet medical needs, leveraging favorable regulatory environments, capitalizing on the rising cancer prevalence, and fostering collaborative innovation, ADCs are set to play a crucial role in the future of targeted cancer therapies. The expansion into new indications offers a wealth of opportunities for the ADC market.
Country Insights
The ADC market is segmented by country into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East and Africa, with Saudi Arabia holding the largest market share in 2023. The rising prevalence of breast cancer is driving the demand for breast cancer therapeutics in South Africa. A 2023 study highlighted that breast cancer is the most common cancer among women in South Africa, with a significant incidence rate. The increasing cancer incidence in South Africa is leading to a higher demand for effective treatment options, including ADCs, which are preferred for their targeted approach that enhances patient outcomes while minimizing side effects. Notable therapies available in South Africa include Brentuximab vedotin for refractory Hodgkin lymphoma and Ado-trastuzumab emtansine for relapsed metastatic HER2+ breast cancer. The presence of major players like Pfizer, AstraZeneca, and Gilead Sciences is also driving market growth through various strategies such as partnerships, collaborations, and product launches.
Company Profiles
Key players in the Middle East and Africa ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
Executive Summary and Market Analysis
The ADC market in the Middle East and Africa is divided into key regions including the UAE, South Africa, Saudi Arabia, and the broader Middle East & Africa. Factors such as government initiatives aimed at enhancing pharmaceutical development and the increasing incidence of cancer are driving market growth in this region. The rise in cancer cases, particularly among aging populations, is a primary driver for the ADC market. Technological advancements in ADCs and ongoing research efforts are improving treatment efficacy, making these therapies increasingly appealing for cancer treatment. Additionally, strategic partnerships and collaborations among biopharmaceutical companies are crucial for accelerating ADC development. Increased healthcare investments and the establishment of local biopharmaceutical infrastructures, especially in countries like Saudi Arabia, further contribute to market expansion.
Strategic Insights
Market Segmentation Analysis
- By Technology: The market is categorized into Cleavable Linker and Non-cleavable Linker, with Cleavable Linker holding the largest market share in 2023.
- By Application: The ADC market is segmented into Blood Cancer, Brain Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, and Others, with Breast Cancer leading in market share in 2023.
- By Target: The market is divided into HER2, CD22, CD30, and Others, with HER2 being the dominant target in 2023.
- By Distribution Channel: The market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies, with Hospital Pharmacies holding the largest share in 2023.
The expansion into new therapeutic indications presents significant opportunities within the ADC market. ADCs are designed to deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues, making them highly versatile. This versatility allows for the exploration of ADC applications beyond their initial focus on hematological malignancies and certain solid tumors. Many cancers currently lack effective treatment options, and the introduction of ADCs targeting new biomarkers can offer innovative therapies for these challenging conditions. For example, ADCs are being researched for treating breast, lung, and bladder cancers, where traditional therapies may fall short. Collaborations between pharmaceutical companies and research institutions are fostering innovation in ADC development, focusing on identifying novel targets and optimizing linker technologies to enhance efficacy and safety. A notable example is the study published in July 2025 in the Journal of the Egyptian National Cancer Institute, which explored Patritumab Deruxtecan, a HER3-directed ADC, for EGFR-mutant non-small cell lung cancer (NSCLC) after resistance to EGFR-TKIs, indicating a shift in ADC applications.
By addressing unmet medical needs, leveraging favorable regulatory environments, capitalizing on the rising cancer prevalence, and fostering collaborative innovation, ADCs are set to play a crucial role in the future of targeted cancer therapies. The expansion into new indications offers a wealth of opportunities for the ADC market.
Country Insights
The ADC market is segmented by country into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East and Africa, with Saudi Arabia holding the largest market share in 2023. The rising prevalence of breast cancer is driving the demand for breast cancer therapeutics in South Africa. A 2023 study highlighted that breast cancer is the most common cancer among women in South Africa, with a significant incidence rate. The increasing cancer incidence in South Africa is leading to a higher demand for effective treatment options, including ADCs, which are preferred for their targeted approach that enhances patient outcomes while minimizing side effects. Notable therapies available in South Africa include Brentuximab vedotin for refractory Hodgkin lymphoma and Ado-trastuzumab emtansine for relapsed metastatic HER2+ breast cancer. The presence of major players like Pfizer, AstraZeneca, and Gilead Sciences is also driving market growth through various strategies such as partnerships, collaborations, and product launches.
Company Profiles
Key players in the Middle East and Africa ADC market include GSK Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, Gilead Sciences Inc, BioNTech SE, Daiichi Sankyo Co Ltd, RemeGen Co Ltd, and ADC Therapeutics SA. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - MIDDLE EAST AND AFRICA MARKET ANALYSIS
6.1 Middle East and Africa Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 Middle East and Africa Antibody Drug Conjugates Market Forecast and Analysis
7. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 Middle East and Africa
11.1.1 Middle East and Africa Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Middle East and Africa Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.4.5.5 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.4.5.5.2 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.4.5.5.3 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.4.5.5.4 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTIBODY DRUG CONJUGATES MARKET LANDSCAPE
4.1 PEST Analysis
4.2 Ecosystem Analysis
4.2.1 Raw Materials and Sourcing
4.2.2 Manufacturing Processes
4.2.3 Regulatory Compliance
4.2.4 Distribution and Logistics
4.2.5 List of Vendors in the Value Chain
5. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTIBODY DRUG CONJUGATES MARKET - MIDDLE EAST AND AFRICA MARKET ANALYSIS
6.1 Middle East and Africa Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
6.2 Middle East and Africa Antibody Drug Conjugates Market Forecast and Analysis
7. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TECHNOLOGY
7.1 Cleavable Linker
7.1.1 Overview
7.1.2 Cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Non-cleavable Linker
7.2.1 Overview
7.2.2 Non-cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY APPLICATION
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Brain Cancer
8.2.1 Overview
8.2.2 Brain Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.4 Ovarian Cancer
8.4.1 Overview
8.4.2 Ovarian Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.5 Lung Cancer
8.5.1 Overview
8.5.2 Lung Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY TARGET
9.1 HER2
9.1.1 Overview
9.1.2 HER2: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 CD22
9.2.1 Overview
9.2.2 CD22: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 CD30
9.3.1 Overview
9.3.2 CD30: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
10.1 Retail Pharmacies
10.1.1 Overview
10.1.2 Retail Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Hospital Pharmacies
10.2.1 Overview
10.2.2 Hospital Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. MIDDLE EAST AND AFRICA ANTIBODY DRUG CONJUGATES MARKET - COUNTRY ANALYSIS
11.1 Middle East and Africa
11.1.1 Middle East and Africa Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.1.1 Middle East and Africa Antibody Drug Conjugates Market Revenue and Forecast and Analysis - by Country
11.1.2.2 South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.1.2.2.1 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.1.2.2.2 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.1.2.2.3 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.1.2.2.4 South Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.2.3.3 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2.3.3.1 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.2.3.3.2 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.2.3.3.3 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.2.3.3.4 Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.3.4.4 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3.4.4.1 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.3.4.4.2 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.3.4.4.3 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.3.4.4.4 United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
11.4.5.5 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4.5.5.1 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Technology
11.4.5.5.2 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Application
11.4.5.5.3 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Target
11.4.5.5.4 Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market Share - by Distribution Channel
12 COMPETITIVE LANDSCAPE
12.1 Heat Map Analysis by Key Players
12.2 Company Positioning & Concentration
13 INDUSTRY LANDSCAPE
13.1 Overview
13.2 New Product Development
13.3 Merger and Acquisition
13.4 Other Strategic Developments
14 COMPANY PROFILES
14.1 GSK Plc
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Pfizer Inc
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Bristol-Myers Squibb Co
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Takeda Pharmaceutical Co Ltd
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 AstraZeneca Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Astellas Pharma Inc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 AbbVie Inc
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Merck KGaA
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Gilead Sciences Inc
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 BioNTech SE
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Products and Services
14.12.4 Financial Overview
14.12.5 SWOT Analysis
14.12.6 Key Developments
14.13 Daiichi Sankyo Co Ltd
14.13.1 Key Facts
14.13.2 Business Description
14.13.3 Products and Services
14.13.4 Financial Overview
14.13.5 SWOT Analysis
14.13.6 Key Developments
14.14 RemeGen Co Ltd
14.14.1 Key Facts
14.14.2 Business Description
14.14.3 Products and Services
14.14.4 Financial Overview
14.14.5 SWOT Analysis
14.14.6 Key Developments
14.15 ADC Therapeutics SA
14.15.1 Key Facts
14.15.2 Business Description
14.15.3 Products and Services
14.15.4 Financial Overview
14.15.5 SWOT Analysis
14.15.6 Key Developments
15. APPENDIX
15.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East and Africa Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 22. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 23. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 24. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 25. Heat Map Analysis by Key Players
Table 1. Middle East and Africa Antibody Drug Conjugates Market Segmentation
Table 2. List of Vendors
Table 3. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 5. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 6. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 7. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 8. Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 9. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 10. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 11. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 12. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 13. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 14. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 15. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 16. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 17. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 18. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 19. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 20. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 21. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Technology
Table 22. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 23. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Target
Table 24. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 25. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Middle East and Africa Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. Middle East and Africa Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East and Africa Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Middle East and Africa Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
Figure 1. Middle East and Africa Antibody Drug Conjugates Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Antibody Drug Conjugates Market
Figure 4. Middle East and Africa Antibody Drug Conjugates Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East and Africa Antibody Drug Conjugates Market Revenue (US$ Million), 2023 - 2031
Figure 7. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Technology, 2023 and 2031
Figure 8. Cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Non-cleavable Linker: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Application, 2023 and 2031
Figure 11. Blood Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Brain Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Breast Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. Ovarian Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Lung Cancer: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Target, 2023 and 2031
Figure 18. HER2: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. CD22: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. CD30: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Others: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Middle East and Africa Antibody Drug Conjugates Market Share (%) - by Distribution Channel, 2023 and 2031
Figure 23. Retail Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Hospital Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Online Pharmacies: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Middle East and Africa Antibody Drug Conjugates Market Breakdown by Key Countries, 2023 and 2031 (%)
Figure 27. South Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. Saudi Arabia: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 29. United Arab Emirates: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Rest of Middle East and Africa: Middle East and Africa Antibody Drug Conjugates Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. Company Positioning & Concentration
